Fennec Pharmaceuticals (FENC) Downgraded by ValuEngine to Sell
ValuEngine cut shares of Fennec Pharmaceuticals (NASDAQ:FENC) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.
Separately, Laidlaw began coverage on Fennec Pharmaceuticals in a report on Wednesday, November 29th. They set a buy rating and a $22.00 target price on the stock.
Fennec Pharmaceuticals (NASDAQ:FENC) opened at $9.20 on Tuesday. Fennec Pharmaceuticals has a twelve month low of $8.00 and a twelve month high of $13.95.
In other Fennec Pharmaceuticals news, major shareholder Spa Essetifin acquired 294,115 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were bought at an average cost of $8.50 per share, with a total value of $2,499,977.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.70% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/20/fennec-pharmaceuticals-fenc-downgraded-by-valuengine-to-sell.html.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc, formerly Adherex Technologies Inc, is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.